Cargando…

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset

BACKGROUND: Clinical relapses are the defining feature of relapsing forms of multiple sclerosis (MS), but relatively little is known about the time course of relapse recovery. OBJECTIVE: The aim of this study was to investigate the time course of and patient factors associated with the speed and suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Marcus W, Moral, Ester, Brieva, Luis, Mostert, Jop, Strijbis, Eva MM, Comtois, Jacynthe, Repovic, Pavle, Bowen, James D, Wolinsky, Jerry S, Lublin, Fred D, Cutter, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687796/ https://www.ncbi.nlm.nih.gov/pubmed/37830451 http://dx.doi.org/10.1177/13524585231202320

Ejemplares similares

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
por: Ben-Zacharia, Aliza Bitton, et al.
Publicado: (2021)

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial
por: Cutter, Gary, et al.
Publicado: (2023)

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials
por: Strijbis, Eva MM, et al.
Publicado: (2022)

MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis
por: Koch, Marcus W, et al.
Publicado: (2021)

Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS
por: W Koch, Marcus, et al.
Publicado: (2021)

Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data
por: Datta, Sushmita, et al.
Publicado: (2015)

Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study()
por: Narayana, Ponnada A., et al.
Publicado: (2012)

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
por: Weinstock-Guttman, Bianca, et al.
Publicado: (2021)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
por: Nixon, Richard, et al.
Publicado: (2014)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Relapsing–remitting painful ophthalmoplegia due to orbital myositis
por: Guaschino, E., et al.
Publicado: (2005)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
por: Xie, Yao, et al.
Publicado: (2020)

Development and Validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding Stressors in Patients
por: Khatibi, Ali, et al.
Publicado: (2020)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Effect of Seasonal Variation on Relapse Rate in Patients With Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
por: Makkawi, Seraj, et al.
Publicado: (2022)

Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study
por: van Gorp, Dennis A.M., et al.
Publicado: (2019)

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
por: O’Connor, Paul W., et al.
Publicado: (2013)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Spinal epidural lipomatosis: An unusual cause of relapsing and remitting paraparesis
por: Rajput, Dinesh, et al.
Publicado: (2010)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_678s0ktjl8h1rifbtp7rg71jgm